Hostname: page-component-848d4c4894-sjtt6 Total loading time: 0 Render date: 2024-07-01T02:36:16.506Z Has data issue: false hasContentIssue false

P-148 - Utilization of Concomitant Anxiolytic Treatment in Benzodiazepine-resistant Patients Initiating Pregabalin or Ssri/snri for the Treatment of Generalized Anxiety Disorder (gad)

Published online by Cambridge University Press:  15 April 2020

E. Alvarez
Affiliation:
Department of Psychiatry, Hospital de la Santa Creu i San Pau, Barcelona
J.L. Carrasco
Affiliation:
Department of Psychiatry, Hospital Clínico San Carlos, Madrid
J.M. Olivares
Affiliation:
Department of Psychiatry, Hospital Meixoeiro, Complejo Hospitalario Universitario, Vigo, Madrid, Spain
V. López-Gómez
Affiliation:
Medical Unit, Pfizer, S.L.U, Madrid, Spain
M. Perez
Affiliation:
Medical Unit, Pfizer, S.L.U, Madrid, Spain
J. Rejas
Affiliation:
Health Economics and Outcomes Research, Pfizer, Madrid, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objectives

SSRI/SNRI and pregabalin are recommended therapies for the treatment of GAD, particularly in case of benzodiazepines refractory (BR) patients. The aim was to compare the use of anxiolytic treatments in BR GAD patients initiating treatment with pregabalin or SSRI/SNRI as add-on therapies.

Methods

BR outpatients with GAD (DSM-IV criteria) enrolled in a prospective, multicentre, observational cohort study were included in this post-hoc analysis. BR was defined as insufficient response with persistence of symptoms of anxiety (HAM-Anxiety scale ≥ 16) after a course of a standard dose of benzodiazepines, for 6 months. The use (% of users and dose) of pregabalin, SSRI/SNRI and benzodiazepines was evaluated during the 6-month study period.

Results

128 subjects treated with pregabalin and 126 with SSRI/SNRI were analyzed. Both cohorts presented a similar pattern of anxiolytic drugs utilization at baseline: Alprazolam (33% pregabalin and 27% SSRI/SNRI), diazepam (20% vs. 11%) and lorazepam (17% vs. 30%) were among the most used benzodiazepines. At the 6 month visit, pregabalin treated patients showed a significant decrease in the % of users of alprazolam (16% vs. 27%; p = 0.032), lorazepam (14% vs. 27%; p = 0.013) or ketazolam (0% vs. 7%; p = 0.002) compared with SSRI/SNRI. 57% of patients in pregabalin group, compared with 87% in SSRI/SNRI, were still receiving a benzodiazepine concomitantly at the 6 month visit (p < 0.001).

Conclusions

Compared with SSRI/SNRI, initiating therapy with pregabalin reduced the use of concomitant anxiolotic treatment in BR outpatients with GAD in routine medical practice.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.